MedTrace Logo

Comparing Palliative Radiotherapy With or Without Carboplatin

NCT03637335 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2018-08-20

No results posted yet for this study

Summary

The study population has locally advanced or metastatic bronchial or head and neck cancer.

This study assesses the value of concomitant chemo/radiotherapy with carboplatin daily during metastatic radiotherapy versus radiotherapy alone.

The realization of a systemic treatment during the radiotherapy could make it possible to obtain a benefit on the control of the evolution of the metastases and thus of the pains generated, as well as on the quality of life of the patients. In addition, a benefit in overall survival is possible.

Conditions

Interventions

COMBINATION_PRODUCT

irradiation + carboplatin

30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin

COMBINATION_PRODUCT

irradiation + placebo

30 Gy en 10 fractions de 3 Gy + 10 injections of placebo

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • FABRICE DENIS, MD · Centre Jean Bernard

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-17
Primary Completion
2017-11-28
Completion
2018-05-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03637335 on ClinicalTrials.gov